GlobeNewsWire
30 Jul 2026, 02:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA stated that Capricor's HOPE-3 study did not meet its pre-specified primary and secondary efficacy endpoints for Deramiocel. — Failure to meet primary endpoints in a pivotal Phase 3 trial severely jeopardizes FDA approval and the drug's commercial viability.
-0.90The FDA reported that Capricor made modifications to its pre-specified statistical analysis plan (SAP), including changes to endpoint definitions and analytical methods. — Post-hoc changes to analysis plans often suggest data manipulation to hide failure, significantly damaging regulatory trust and credibility.
-0.70Law firm Hagens Berman has opened an investigation into whether Capricor misled investors regarding the efficacy and trial results of Deramiocel. — Legal investigations and potential class-action lawsuits create additional financial liability and institutional selling pressure.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company's stock crashed over 60% following FDA findings that its lead product candidate failed to meet efficacy endpoints, leading to a legal investigation into investor fraud.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
7h ago
